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Introduction
Naratriptan (NAR), a 5-hydroxy tryptamine agonist, is used in the treatment of acute phase migraine as the hydrochloride salt (NAR.HCl). The drug is administered orally as a conventional tablet (1) . Unfortunately, formulations currently available are not associated with good patient compliance because of related gastrointestinal adverse reactions (2) . Buccal drug delivery (BDD) may offer an alternative route for administration of NAR with minimal side effects. This requires the active to permeate through the buccal epithelium in sufficient amounts to achieve effective therapeutic plasma concentrations. Orally disintegrating tablets of NAR.HCl were prepared and characterised by Stange et al. (3) . However the ability of these preparations to deliver the drug across buccal tissue was not evaluated.
The penetration of a molecule through the hydrophilic and lipophilic domains of the buccal tissue depends largely on its physicochemical properties (4, 5) . Molecules, which are administered transdermally, have also been developed as commercial oral transmucosal preparations (6) . This suggests that the desirable properties for buccal delivery are similar to those for drugs delivered transdermally for systemic effects. Typically these include low melting point, molecular weight (MW) < 500 and balanced log P values (7) . Ionisation will also influence permeation; greater transmucosal permeation has been observed for the unionised forms of a number of actives compared with their salts (8) (9) (10) . Holm et al. (11) demonstrated pH-dependent permeation for metoprolol both in vitro and in vivo using porcine models with greater permeation at higher buffer pH values.
The aims of the present work were therefore to:
Prepare and characterise NAR base from the salt form.
(ii) Determine the solubility and stability of NAR in a range of candidate vehicles.
(iii) Compare the buccal permeation characteristics of the base with the salt using an in vitro porcine buccal model.
Materials and Methods

Materials
NAR HCl was obtained from Bioprogress (March, UK). Ethanol (ET), 99.7-100%
(v/v) AnalaR ® grade was supplied by VWR (UK). Transcutol P ® (TC), Labrafac PG Waters, Ireland) was used to determine the purity of both species when dissolved in methanol. The chromatographic column was an Onyx™ Monolithic C 18 , LC Column (50 x 4.6 mm). The volume of injection was 10 µL and the column was maintained at 35ºC. The flow rate was 1.5 mL/min, and the run time was 10 min. A gradient method was used for analysis with the mobile phase consisting of 0.1% formic acid in water and acetonitrile.
High Performance Liquid Chromatographic (HPLC) analysis
A stock solution of 100 µg/mL of NAR in water was used to prepare a series of concentrations ranging from 0.5 -30 µg/mL. These standards were used to construct a calibration curve for HPLC analysis (Agilent 1100, USA operated with ChemStation cartridge (20 × 4.6 mm, 5µm) was used for analysis. Ultraviolet (UV) detection at 284 nm was employed; the injection volume was 10 µL and the column temperature was maintained at 40ºC. The mobile phase solution consisted of 0.1% TFA in water with ACN (78:22, v/v).
The flow rate was 1 mL/min, and the run time was 8 min. Under these conditions, NAR exhibited a retention time of 5.4 ± 0.1 min. The HPLC method was validated in terms of specificity, linearity, accuracy, precision, detection limit and quantification limit according to
International Conference of Harmonization guidelines (12) . The limit of detection was 0.23 µg/mL while the limit of quantification was 0.7 µg/mL.
Solubility studies, solubility parameter and stability
For solubility determination in candidate vehicles an excess amount of NAR was added to one mL of solvent in a reaction tube and sonicated for five minutes. The suspensions were kept at 37ºC for 2 days with continuous rotation. Thereafter, the tubes were centrifuged and 50 µL of the clear supernatant was diluted and quantified by HPLC. Experiments were performed in triplicate and mean values with standard deviations (SD) were calculated (13, 14) . To determine solubility at different pH values, excess NAR was added to PBS to which a few drops of 0.1M HCl or 0.1M NaOH were added to obtain the required pH value.
Suspensions were stirred for 48 h at room temperature. The pH was measured using a 
Determination of partition (log P) and distribution coefficients (log D)
For the determination of log P, octanol pre-saturated with water and water pre-saturated The log of the partition coefficient or distribution coefficient was calculated using the relative NAR concentrations in n-octanol / water or n-octanol / pH adjusted PBS. All measurements were conducted at room temperature and in triplicate.
In vitro permeation experiments
Porcine buccal tissue was obtained from a local abattoir immediately after slaughter and was transported on ice. All experiments were conducted with fresh tissue. The buccal mucosa was separated from the underlying tissues with surgical scissors and a scalpel blade.
The mucosa was trimmed using a dermatome to a thickness of 0. PEG 200, or PEG 400 at a concentration of 2.5 mg/mL and 1 mL was applied to the donor chamber. NAR was dissolved in TC and DPG at concentrations of 2.5 mg/mL and 25 mg/mL (as the current therapeutic dose is 2.5 mg) to study the effect of dose on NAR buccal delivery; 100 µL was applied in the donor chamber. To study the influence of pH on NAR buccal delivery, the donor chamber was charged with 1 mL of saturated drug solution in PBS (pH= 7.4, 8.5, 9.5, and 10). The cumulative amount of drug permeated per unit area of buccal mucosa (µg/cm 2 ) was plotted against the collection time (6 h) and reported as Q 6h ; the slope of this graph at the steady state was considered as the flux (J ss ) and the extrapolated x-axis intercept as the lag time (t lag ). The permeability coefficient (k p ) was determined as reported previously (17) .
Mass balance studies were conducted to quantify the amount of drug in the different compartments of the Franz cells as well as in the tissue. Initially, the remaining amount of formulation on the tissue was pipetted out, diluted and analysed using HPLC. Secondly, the surface of the membrane was washed three times sequentially with 1 mL of methanol:water recovery of the applied active for the washing procedure and 96% recovery for the extraction step.
Statistical analysis
The data were analysed using a software package (SPSS version 22) and Excel (Microsoft Office 2010). All results are presented as mean ± standard deviation (SD). The Student's t-test and one-way analysis of variance (ANOVA) with replication using the Post Hoc Tukey test were used to investigate statistical differences. A probability of p < 0.05 was considered statistically significant.
Results and Discussion
Thermal, elemental and LC-MS analyses
The molecular weight and the melting point for NAR (Figure 1 ) are 335.4 g/mole and 170° to 171°C and the corresponding values for NAR.HCl are 371.9 g/mole and 237° to 239° C, respectively (18) . NAR base prepared following drying had the appearance of a white powder. Visual inspection suggested that the precipitate collected after dissolution in ethyl acetate and evaporation was crystalline. The percentage yield of the resultant precipitate was 78 ± 5 %, with some of the drug likely being lost during the washing steps. Figure 2 shows the thermograms for the salt and the base prepared from aqueous solution or from ethyl acetate. The precipitate recrystallised from ethyl acetate shows a thermal curve similar to that for the salt with a gradual slope around 170°C (near the melting point of NAR base).
However the thermogram of the base prepared without ethyl acetate indicates the presence of some residual water molecules in the sample. DSC analysis was consistent with the TGA results. Figure 3 shows the DSC scan for the salt and the base prepared from ethyl acetate.
The melting point for NAR.HCl is 248°C and this peak was absent in the thermogram of the base, which clearly indicated the complete conversion of the salt to the base. The presence of a single endothermic sharp peak confirmed that the entire drug was converted to a form with a melting point of 178ºC. CHN analysis indicated good agreement between the practical and theoretical mass fractions of C, H and N atoms in NAR.HCl, and in the base prepared from ethyl acetate. A single peak was obtained for the LCMS analysis confirming the purity of the sample. This sample was used in all subsequent studies because of the residual water in the product recrystallised from the aqueous solution.
Solubility, solubility parameter and stability results
Solubility and stability studies were conducted in a range of solvents commonly used in topical and transdermal preparations (Figure 4) . NAR was noted to be stable in all the tested solvents when incubated at 37ºC for 3 days. in OA may reflect association of the positive charge of the tertiary amine group of NAR and the carboxylic acid moiety of OA. The maximum solubility of NAR.HCl was determined in water (27.3 ± 0.5 mg/mL) followed by PG (14.9 ± 0.4 mg/mL), PEG 200 (10.9 ± 0.6 mg/mL), PEG 400 (3.1 ±0.1 mg/mL) and TC (1.0 ± 0.1 mg/mL).
Partition and distribution coefficients
The average log P of NAR for the three octanol:water ratios investigated was determined to be 0.63 ± 0.08 with a total drug recovery of 96.7% ± 1.7. NAR has two different pK a values as a result of (i) A basic piperidine ring -pK a 9.6, and (ii) An acidic sulfamide group -pK a 10.6. At pH 10 around 60% of NAR is present in the unionised form and the drug shows the highest log D and lowest solubility, while at physiological pH (6.8 to 7.4) the situation is reversed. Figure 5 shows the change in Log D value as a function of pH with solubility values of NAR ranging from 16.8 mg/ml at pH 7.4 to 0.3 mg/ml at pH 10.
In vitro permeation studies
Single solvents Permeation studies for NAR were conducted in the two solvents for which NAR exhibited the highest solubility. The permeation profiles for two concentrations of NAR in TC and DPG (2.5 mg/ml and 25 mg/ml) across porcine buccal mucosa over 6 h are shown in Figure 6 ; permeation parameters are summarised in (Figure 6 , Table 1 ). These findings are consistent with NAR permeation across the buccal mucosa being a passive diffusion process.
pH permeation studies
To understand the influence of pH on NAR buccal delivery, the permeability was determined in phosphate buffer saline (PBS) in the pH range 7.4 -10. This range was selected to encompass the pK a value associated with the piperidine ring of NAR (9.6). The permeation profiles (expressed as percentage of applied dose) over 8 h following application of 1 mL of saturated solutions of NAR are shown in Figure 7 . Table 2 summarises NAR permeability coefficients, percentages permeated over 8 h, unionised fractions and distribution coefficients for the pH range studied. Although tissue integrity was not evaluated at the end of these permeation experiments, other researchers report no epithelial changes for experiments conducted with excised porcine tissue in the pH range 7.4 -9.0 (23). These authors also reported no significant differences in lag times for mannitol permeation for studies conducted at pH 7.4 compared with pH 9.0; surprisingly, lag times for studies conducted at pH 8.5 were significantly longer than for pH 7.4.
The permeability coefficient (k p ) of NAR increased significantly (ANOVA, p < 0.05) with pH. A seven-fold increase in the buccal permeability coefficient and a ten-fold increase in the percentage of drug which permeated were observed over the pH range studied. The increase in the k p values and the fraction of NAR permeated after 8 h at the higher pH values are in line with the increase of the fraction of unionised species and the calculated distribution coefficients. There are two major routes for drug permeation through the buccal mucosal membrane: paracellular and transcellular (24). It has also been suggested that if the drug is transported through the paracellular route (without partitioning), pH should not affect drug absorption rate. For the transcellular pathway the drug absorption rate is pH dependent.
Porcine buccal tissue has been used to model oral transmucosal delivery of a wide range of drug molecules in vitro (6) . Histological features of porcine buccal tissue are reported to be similar to those of humans as well as its permeability to water (25,26). The influence of various experimental variables on drug permeation in such ex vivo models has also been studied extensively (20, 27-28). Recently, the relationship between drug permeation in ex vivo porcine and human buccal tissue models has also been explored (23). Although porcine tissue was approximately two-fold more permeable to metoprolol than human tissue a good correlation between the two models was observed (r 2 =0.96). Histomorphological examination also confirmed similar features for tissue from the two species.
The maximum amount of NAR which permeated after 6 h was ~130 µg/cm 2 when dosed at 25 mg/ml in Transcutol™ (100 µl application). The mean plasma concentration and clearance values of NAR following oral administration are reported as 8 µg/L (ranging from 5.9-10.7 µg/L) and 6.6 mL/min/kg (18) . Assuming a 70 kg patient and calculating NAR input from the flux values in Table 1 
Conclusions
NAR was prepared and characterised from its hydrochloride salt; Log D and Log P values were also determined. Solubility and stability screening was conducted for a range of single solvents. Although no buccal permeation was observed for NAR.HCl this is the first report of buccal permeation of NAR. There is scope to optimise further these simple vehicles for buccal delivery which will be explored in a future paper. NAR permeated porcine buccal 
